Krieg DeVault LLP

340B Hot Topics: Courts, Surveys, and Rebates, with Jason Prokopik

Overview
Toggle Button Open

May 7, 2026

By: Brandon W. Shirley

"Legal issues intersect with non-legal issues in [the] 340B space,” says Brandon Shirley, a partner at Krieg DeVault, who teams up with Jason Prokopik, PharmD, Senior Manager & Pharmacy Consultant at Blue & Co., LLC to host this rapid-fire 340B review. Following the 340B Coalition Conference in San Diego in February 2026, they tackled five hot topics: the CMS Medicare survey for 340B hospitals; a court ruling regarding child site activation; the status of the rebate model pilot; Indiana's new mandatory 340B reporting requirement and the proposed Indiana Medicaid restrictions on 340B drug submissions; and a Ninth Circuit False Claims Act ruling against drug manufacturers. Tune in to learn more about each of these developments.

Disclaimer: The contents of this article should not be construed as legal advice or a legal opinion on any specific facts or circumstances. The contents are intended for general informational purposes only, and you are urged to consult with counsel concerning your situation and specific legal questions you may have.

Practices & Industries
Toggle Button Open

Practices

  • Health Care
  • Pharmacy Law

Industries

  • Health Care
  • Pharmacy Law
  • Krieg DeVault Podcast Series
  • Firm News and Events
  • Thought Leadership

Filter by Service

  • Overview
  • Practices & Industries

May 7, 2026

By: Brandon W. Shirley

"Legal issues intersect with non-legal issues in [the] 340B space,” says Brandon Shirley, a partner at Krieg DeVault, who teams up with Jason Prokopik, PharmD, Senior Manager & Pharmacy Consultant at Blue & Co., LLC to host this rapid-fire 340B review. Following the 340B Coalition Conference in San Diego in February 2026, they tackled five hot topics: the CMS Medicare survey for 340B hospitals; a court ruling regarding child site activation; the status of the rebate model pilot; Indiana's new mandatory 340B reporting requirement and the proposed Indiana Medicaid restrictions on 340B drug submissions; and a Ninth Circuit False Claims Act ruling against drug manufacturers. Tune in to learn more about each of these developments.

Disclaimer: The contents of this article should not be construed as legal advice or a legal opinion on any specific facts or circumstances. The contents are intended for general informational purposes only, and you are urged to consult with counsel concerning your situation and specific legal questions you may have.

Practices

  • Health Care
  • Pharmacy Law

Industries

  • Health Care
  • Pharmacy Law
  • Krieg DeVault Podcast Series
  • Firm News and Events
  • Thought Leadership

Filter by Service

 

© 2026 Krieg DeVault LLP. All Rights Reserved.